CTI BIOPHARMA CORP. CTIC Cash Flow

Cti biopharma corp. (CTIC)

CashFlow / Yearly

Dec'19	Dec'18	Dec'17	Dec'16	Dec'15	Dec'14	Dec'13	Dec'12	Dec'11	Dec'10	Dec'09
Operating activities
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
-40,023	-29,352	-40,831	-52,953	-120,763	-94,229	-43,550	-101,687	-62,619	-82,836	-
Adjustments to reconcile net loss to net cash used in operating activities:
Baxalta milestone revenue
-	-	-	32,000	0	0	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-95,395
Acquired in-process research and development
-	-	-	-	-	21,859	0	29,108	-	-	-
Equity-based compensation
5,200	6,400	5,700	13,324	14,828	20,196	9,066	7,938	5,017	17,048	24,937
Depreciation and amortization
546	600	700	831	990	1,100	1,600	2,346	2,411	1,842	1,771
Loss on debt extinguishment
-	-	-163	0	-1,211	0	0	-	-	-	-
Sublease Income (Loss)
-	-	-1,584	0	0	-	-	-	-	-	-
Gain on dissolution of foreign entities
1,332	4,288	0	-	-	-	-	-	-	-	-
Provision for bad debt
-	-	-	1,735	0	0	-	-	-	-	-
Reserve for excess, obsolete or unsalable inventory
-	-	-	692	1,326	0	0	-	-	-	-
Other-than-temporary impairment on available-for-sale securities
-	-	-	520	0	0	-	-	-	-	-
Gain on sale of investment in joint venture
-	-	-	-	-	-	-	-	-	-	10,244
Noncash interest expense
521	525	163	214	390	729	513	0	546	768	5,788
Noncash rent benefit
653	1,424	648	467	409	354	-	-	-	-	-
Foreign Currency Transaction Gain (Loss), Unrealized
-	-	0	-	-	-	-	-	-	-	-
Change in value of warrant liability
-	-	-	0	-232	886	0	-	-	-	-
Debt conversion expense
-	-	-	-	-	-	-	-	-	2,031	-
Provision for VAT Assessments
-	-	-	-	-	600	0	-3,402	-	3,503	-
Gain on derivative liabilities
-	-	-	-	-	-	-	-	-	-	7,218
Gain on exchange of convertible notes
-	-	-	-	-	-	-	-	-	-	7,381
Equity loss from investment in joint venture
-	-	-	-	-	-	-	-	-	-	-1,204
Milestone modification expense
-	-	-	-	-	-	-	-	-	-	6,000
Noncontrolling interest
-	-	-	-	-	-	-	-	-	-	-252
Other
-191	-794	18	0	0	20	-365	-5	1,958	450	487
Changes in operating assets and liabilities:
Restricted cash
-	-	-	-	-	-	-	-	-	-	-6,640
Accounts receivable
-	-	-402	156	-1,555	1,980	227	-	-	-	-991
Receivables from license and development services arrangements
-13,674	12,389	-6,579	-	-	-	-	-	-	-	-
Receivables from collaborative arrangements
-	-	-	9,476	0	0	-	-	-	-	-
Inventory
-	-	-1,120	-567	402	-305	3,254	1,586	-	-	-
Prepaid expenses and other assets
-1,120	163	-326	-1,609	402	-46	-4,530	3,759	-567	-516	2,649
Accounts payable and accrued expenses
-5,463	923	-	-	-	-	-	-	-	-	-
Deferred revenue and other
-1,569	-1,412	-	-	-	-	-	-	-	-	-
Other assets
-	-	-63	-355	-826	356	846	-1,495	2,452	381	-519
Accounts payable
-	-	-4,730	-3,025	4,368	1,454	-5,774	3,123	-310	-1,403	-1,484
Accrued expenses
-	-	-11,096	2,620	2,426	10,250	-834	-885	-211	-3,787	-10,750
Deferred revenue
-	-	790	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-1,071	-918	-31	2,636	-	-	-	-
Other liabilities
-	-	374	1	3	-5	-25	4,528	-1,449	21	-176
Total adjustments
-	-	-	-23,727	25,560	54,679	7,720	38,911	2,161	19,708	7,209
Net cash used in operating activities
-27,822	-39,824	-39,296	-76,680	-95,203	-	-	-	-60,458	-63,128	-88,186
Net cash used in operating activities
-	-	-	-	-	-39,550	-35,830	-62,776	-	-	-
Investing activities
Purchases of securities available-for-sale
-	-	-	-	-	-	-	-	-	350	-
Proceeds from maturities of securities available-for-sale
-	-	-	-	-	-	-	-	-	-	600
Purchases of property and equipment
0	33	49	137	78	333	1,657	2,937	2,703	2,011	1,478
Purchases of short-term investments
11,018	42,067	0	-	-	-	-	-	-	-	-
Proceeds from maturities of short-term investments
39,150	11,610	0	-	-	-	-	-	-	-	-
Proceeds from sale of available-for-sale securities
-	-	11	-	-	-	-	-	-	-	-
Proceeds from sales of property and equipment
-	-	-	-	-	-	123	-	31	85	887
Cash paid for acquisition of assets from S*BIO Pte Ltd.
-	-	-	-	-	-	-	17,764	-	-	-
Other
-	-	-	0	0	208	0	-	-	-	-
Cash received for disposition of Zevalin to joint venture, net
-	-	-	-	-	-	-	-	-	-	6,844
Proceeds received from sale of investment in joint venture, net
-	-	-	-	-	-	-	-	-	-	14,987
Net cash provided by investing activities
28,132	-30,490	-38	-137	-78	-	-	-	-2,672	-2,276	21,840
Net cash used in investing activities
-	-	-	-	-	-541	-1,534	-20,701	-	-	-
Financing activities
Proceeds from rights offering, net of issuance costs
0	64,170	0	0	15,147	0	0	-	-	-	-
Proceeds from issuance of preferred stock, net of issuance costs
-	-	42,669	-	-	-	-	-	-	-	-
Proceeds from Silicon Valley Bank debt, net of issuance costs
-	-	15,971	-	-	-	-	-	-	-	-
Principal payments on debt
5,333	444	19,548	5,452	4,659	1,526	0	-	-	-	-
Proceeds from stock option exercises
-	-	0	-	-	-	-	-	-	-	-
Payments of Stock Issuance Costs
275	268	0	-	-	-	-	-	-	-	-
Payment of a Hercules fee
-	-	-	1,275	0	0	-	-	-	-	-
Payment of tax withholding obligations related to restricted stock awards
0	21	87	355	604	178	247	-	-	-	-
Proceeds from stock option exercises and ESPP stock issuance
1	54	-	-	-	-	-	-	-	-	-
Proceeds from ESPP stock issuance
-	-	10	-	-	-	-	-	-	-	-
Cash paid for repurchase of fractional shares
-	-	36	-	-	-	-	-	-	-	-
Cash paid for the exchange of convertible notes, net of transaction costs
-	-	-	-	-	-	-	-	-	-	9,965
Cash paid for repurchase of shares in connection with taxes on restricted stock vesting
-	-	-	-	-	-	-	-	-	-	6,394
Payment of deemed dividends on conversion of preferred stock
-	-	-	-	-	-	-	-	-	-	3,000
Payment of dividends on preferred stock
-	-	-	-	-	-	-	-	-	-	111
Other
-	-	-	30	165	280	3	-214	-424	-928	-183
Net cash used in financing activities
-	-	-	-	-	36,026	58,972	87,216	-	-	-
Net cash provided by (used in) financing activities
-5,607	63,491	38,979	-7,366	152,017	-	-	-	87,004	49,722	94,775
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	3,359	-405	-355	529	520	-690
Effect of exchange rate changes on cash and cash equivalents
2	44	-429	3	513	-	-	-	-	-	-
Net increase in cash and cash equivalents
-5,295	-6,779	-784	-84,180	57,249	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-706	21,203	3,384	24,403	-15,162	27,739
Supplemental disclosure of cash flow information
Cash paid during the period for interest
1,044	1,197	1,970	-	-	-	-	-	-	-	-
Cash paid during the period for interest
-	-	-	4,446	2,067	1,894	933	16	1,025	3,137	12,047
Cash paid during the period for taxes
-	-	-	-	-	-	-	-	0	0	0
Supplemental disclosure of noncash financing and investing activities
Exchange of common stock and preferred stock for preferred stock
0	24,080	0	-	-	-	-	-	-	-	-
Exchange of common stock and preferred stock for preferred stock
-	-	41,579	-	-	-	-	-	-	-	-
Issuance of Series F preferred stock for Series A, B and C convertible preferred stock
-	-	-	-	-	-	-	-	-	-	3,931
Issuance of common stock upon exercise or exchange of common stock purchase warrants
-	-	-	-	-	1,877	0	17,798	17,485	-	-
Repayment and issuance of Hercules debt
-	-	-	0	13,815	0	0	-	-	-	-
Baxalta milestone advance - earned in lieu of repayment
-	-	-	32,000	0	0	-	-	-	-	-
Preferred stock issuance costs included in accounts payable and accrued expenses
-	-	-	0	0	-	-	-	-	-	-
Issuance of common stock in exchange for Series A 3% convertible preferred stock
-	-	-	-	-	-	-	-	-	-	688
Issuance of common stock in exchange for Series D 7% convertible preferred stock
-	-	-	-	-	-	-	-	-	-	1,793
Issuance of common stock in exchange for convertible notes
-	-	-	-	-	-	-	-	-	-	35,193
Issuance of common stock in exchange for milestone modification
-	-	-	-	-	-	-	-	-	-	6,000
Redemption of Series 8 and 10 preferred stock
-	-	-	-	-	-	-	-	36,638	-	-